ESSA Pharma Cultura da Companhia

Dr. Raymond Andersen, Ph.D., serves as the Chief Technical Officer at ESSA Pharma Inc. since October 11, 2010 and serves as its Secretary since January 6, 2009. Dr. Andersen is a Co-Founder of ESSA. Dr. Andersen served as the Secretary of the ESSA Pharma since January 2009. Dr. Andersen is responsible for participating in the research and development of ESSA's drug candidates and with the assessment and review of business and scientific matters. As an independent consultant, he devotes approximately 20% of his time to the affairs of the Company. He is also a Professor at UBC in the departments of Chemistry and Earth & Ocean Sciences. He is internationally known for his research into the identity and structure of novel chemical compounds derived from marine organisms, the molecular routes to their biosynthesis, their role in ocean ecology and their potential as new drugs. His discoveries represented core technologies of the UBC spinoff companies Aquinox Pharmaceuticals Inc. and Inflazyme Pharmaceuticals. His industrial programs have led to deals with Aventis and Wyeth and the venture capital arms of Johnson & Johnson and Pfizer. He has been a Director at ESSA Pharma Inc. since October 11, 2010. He recognition of his pioneering achievements, Dr. Andersen was inducted into the Royal Society of Canada and received the R. U. Lemieux Award from the Canadian Society for Chemistry and the Jacob Biely Research Prize from UBC. Dr. Andersen's consulting agreement contains non-competition and confidentiality clauses. Dr. Andersen received his B.Sc. degree from the University of Alberta, a M.Sc. from the University of California, Berkeley and Ph.D. from the University of California, San Diego. He carried out post-doctoral research at the Massachusetts Institute of Technology.

Dr. Marianne D. Sadar, Ph.D., serves as Chief Scientific Officer at ESSA Pharma Inc. since October 11, 2010. Dr. Sadar is one of the co-founders of ESSA. She is responsible for participating in the research and development of ESSA's drug candidates and with the assessment and review of business and scientific matters. She is an independent consultant. She served as the President of ESSA Pharma Inc. since January 6, 2009 until October 11, 2010. She has over 20 years of experience in developing treatments for prostate cancer. She has been a Director at ESSA Pharma Inc. since January 6, 2009. She has been a Trustee of Canada Science & Technology Museum Corporation since November 01, 2017. She is a Distinguished Scientist at the BC Cancer Agency's Genome Sciences Centre and a Professor of Pathology and Laboratory Medicine at University of British Columbia. Dr. Sadar has served as President of the Society of Basic Urologic Research (USA), Member of the Scientific Advisor Boards for the Prostate Cancer Foundation (USA) and Coalition to CureProstate Cancer (Canada). She is internationally known for her research on identifying mechanisms of activating the AR and developing therapeutics for advanced prostate cancer that target the N-terminal domain of the AR. Her research was the first to show that the N-terminal domain of the AR could be activated by alternative pathways and she proposed this domain as a therapeutic target in 1999. Later, Dr. Sadar provided the first proof-of-concept that targeting the N-terminus of the AR results in a therapeutic response in an in vivo model of CRPC. She has served on approximately 50 scientific panels and has been a recipient of awards including the Terry Fox Young Investigator Award, Simon Fraser University Alumni Award for Academic Excellence and the first non-American to receive the Society of Women in Urology/Society of Basic Urologic Research Award for Excellence in Research. The Congressionally Directed Medical Research Programs Prostate CancerResearch Program (PCRP) of U.S. Department of Defense recently named Dr. Sadar to the PCRPIntegration Panel. Dr. Sadar received her B.Sc. from Simon Fraser University and Ph.D. from the University of Bradford, U.K. She carried out post-doctoral training at AstraZeneca (Astra H'ssle), Department of Drug Metabolism and Pharmacokinetics in M???lndal, Sweden and at the BC Cancer Agency.

Mr. David S. Wood, MBA, CPA, CMA, has been the Chief Financial Officer of ESSA Pharma Inc. since July 2013 and serves as its Principal Accounting Officer. Mr. Wood is responsible for managing all financial aspects of ESSA Pharma, including financial reporting, treasury and matters related to compliance and corporate governance, insurance, human resources and facilities. Mr. Wood has over 30 years' experience in management positions in both large corporations and early stage companies in North America and the U.K. Mr. Wood served as the Head of Finance & Corporate Development at Celator Pharmaceuticals, Inc. until March 31, 2013 and also served as its Secretary and Treasurer from 2003 to 2013. Mr. Wood has held management positions in both large corporations and early stage companies in Canada and the UK. He served as Managing Director of Cubist Pharmaceuticals (UK) Ltd. Prior to that, he was Senior Director, International Operations of Cubist Pharmaceuticals Inc. and Finance Director at TerraGen Discovery, Inc. He served on the governing body of the National Research. During over 15 years working in the biopharmaceutical industry, he has overseen several merger and acquisition transactions and numerous financings which raised over $100 million. Mr. Wood began his career in the finance and exploration departments at Chevron Corp. He received an M.B.A. from the University of Western Ontario, a B.Sc. Honors in Biology, Queen's University and a CPA, CMA accounting designation.

Han-Jie Zhou serves as the VP, Chemistry and CMC of ESSA Pharmaceuticals. Han-Jie currently resides in the San Francisco Bay Area.